KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Operating Leases (2019 - 2025)

Historic Operating Leases for Guardant Health (GH) over the last 7 years, with Q3 2025 value amounting to $211.8 million.

  • Guardant Health's Operating Leases rose 722.38% to $211.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $211.8 million, marking a year-over-year increase of 722.38%. This contributed to the annual value of $164.3 million for FY2024, which is 1159.87% down from last year.
  • As of Q3 2025, Guardant Health's Operating Leases stood at $211.8 million, which was up 722.38% from $218.6 million recorded in Q2 2025.
  • Guardant Health's 5-year Operating Leases high stood at $241.9 million for Q1 2022, and its period low was $164.3 million during Q4 2024.
  • Moreover, its 5-year median value for Operating Leases was $218.6 million (2025), whereas its average is $213.8 million.
  • Its Operating Leases has fluctuated over the past 5 years, first soared by 44385.42% in 2021, then plummeted by 1159.87% in 2024.
  • Guardant Health's Operating Leases (Quarter) stood at $226.1 million in 2021, then decreased by 7.09% to $210.0 million in 2022, then decreased by 11.51% to $185.8 million in 2023, then fell by 11.6% to $164.3 million in 2024, then grew by 28.91% to $211.8 million in 2025.
  • Its Operating Leases was $211.8 million in Q3 2025, compared to $218.6 million in Q2 2025 and $190.0 million in Q1 2025.